Results for conclusive evidence translation from Danish to Finnish

article 26 evidence 1 .
article 26 evidence 1 .

den europæiske unions tidende article 26 evidence
euroopan unionin virallinen lehti article 26 evidence

for the per kilometre car allowance fuel bills are required as evidence .
for the per kilometre car allowance fuel bills are required as evidence .

any additional information and evidence requested by the ecb shall be supplied within two weeks of such request being made .
any additional information and evidence requested by the ecb shall be supplied within two weeks of such request being made .

for the per km car allowance , please provide fuel / toll receipts as evidence of your travel by car .
for the per km car allowance , please provide fuel / toll receipts as evidence of your travel by car .

further technical details relating to the icm are contained in appendix i. title vii compensation , liability regime and evidence article 24 compensation scheme
further technical details relating to the icm are contained in appendix i. title vii compensation , liability regime and evidence article 24 compensation scheme

electronic or written records of the messages retained by the ecb or by the network service provider shall be accepted as a means of evidence of the payments processed through the ecb .
electronic or written records of the messages retained by the ecb or by the network service provider shall be accepted as a means of evidence of the payments processed through the ecb .

the saved or printed version of the original message of the network service provider shall be accepted as a means of evidence , regardless of the form of the original message .
the saved or printed version of the original message of the network service provider shall be accepted as a means of evidence , regardless of the form of the original message .

når der foreligger tilstrækkelig »weight of evidence« for, om en bestemt farlig egenskaber til stede eller ikke er til stede:
kun on saatavilla riittävästi näyttöä siitä, onko aineella tietty vaarallinen ominaisuus tai ei:

111 « monetary transmission : empirical evidence from luxembourg firm level data » af p. lünnemann og t. mathä , december 2001 .
joulukuu 2001 . 111 lünnemann p. ja mathä t. , monetary transmission : empirical evidence from luxembourg firm level data .

136 « retail bank interest rate pass-through : the new evidence at the euro area level » af g. de bondt , april 2002 .
136 de bondt g. , retail bank interest rate pass-through : new evidence at the euro area level . huhtikuu 2002 .

100 « transmission of monetary policy shocks in finland : evidence from bank level data on loans » af j. topi og j. vilmunen , december 2001 .
joulukuu 2001 . 100 topi j. ja vilmunen j. , transmission of monetary policy shocks in finland : evidence from bank level data on loans .

note for guidance on non- clinical testing of herbal drug preparations with long- term marketing experience - guidance to facilitate mutual recognition and use of bibliographic data concept paper for a note for guidance on the investigation of biopharmaceutical characterisation and bioavailability/ bioequivalence of herbal drugs/ preparations position paper on the risk associated with the use of herbal products containing estragole position paper on the risk associated with the use of herbal products containing methyleugenol position paper on the risk associated with the use of herbal products containing á - and β- asarone position paper on the use of sassafras albidum as active substance or ingredient in herbal medicinal products concept paper on the levels of scientific evidence required for the authorisation of well- established use and traditional herbal medicinal products core- data on urticae radix core- data on lini semen core- data on rosmarini folium cum flore core- data on primulae radix
note for guidance on non- clinical testing of herbal drug preparations with long- term marketing experience - guidance to facilitate mutual recognition and use of bibliographic data concept paper for a note for guidance on the investigation of biopharmaceutical characterisation and bioavailability/ bioequivalence of herbal drugs/ preparations position paper on the risk associated with the use of herbal products containing estragole position paper on the risk associated with the use of herbal products containing methyleugenol position paper on the risk associated with the use of herbal products containing a - and β- asarone position paper on the use of sassafras albidum as active substance or ingredient in herbal medicinal products concept paper on the levels of scientific evidence required for the authorisation of well- established use and traditional herbal medicinal products core- data on urticae radix core- data on lini semen core- data on rosmarini folium cum flore core- data on primulae radix